search
Back to results

Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty

Primary Purpose

Knee Osteoarthritis

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Neuromuscular electrical stimulation
Sponsored by
University of Vermont
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Knee Osteoarthritis

Eligibility Criteria

50 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • symptomatic, primary knee osteoarthritis (OA)
  • being considered for total knee arthroplasty

Exclusion Criteria:

  • knee OA secondary to inflammatory/autoimmune disease
  • untreated/uncontrolled hypertension, diabetes or thyroid disease
  • chronic heart failure, actively-treated malignancy, exercise-limiting peripheral vascular disease, stroke or neuromuscular disease
  • body mass index >38 kg/m2
  • lower extremity blood clot or known coagulopathies
  • implanted pacemaker/ICD

Sites / Locations

  • University of Vermont College of MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

NMES

Control

Arm Description

Neuromuscular electrical stimulation (NMES) will be administered for 5 weeks post-TKA in the quadriceps of the surgical leg. Treatment will occur 5 days per week, twice daily for 45 minutes on each occasion.

No intervention will be administered during the 5 weeks post-TKA in the surgical leg.

Outcomes

Primary Outcome Measures

Cross-sectional area of muscle fibers
Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types
Intermyofibrillar mitochondrial content
Area fraction of intermyofibrillar mitochondria will be assessed by electron microscopy
Maximal calcium-activated tension single muscle fiber tension and shortening velocity
Tension (force per unit muscle fiber cross-sectional area) from segments of chemically-skinned single human muscle fibers will be assessed under maximal calcium-activated condition and shortening velocity will be evaluated from isotonic load clamps, with muscle fiber type determined post-measurement by gel electrophoresis
Mitochondrial function
Oxygen consumption rate of isolated muscle mitochondria under adenosine diphosphate stimulation and hydrogen peroxide production

Secondary Outcome Measures

Physical activity level
Physical activity will be assessed by accelerometry.
Quadriceps muscle cross-sectional area
Quadriceps muscle cross-sectional area will be assessed by computed tomography at the mid-thigh.
Physical functional measures
Whole body physical function will be assessed.
Whole muscle strength
Knee extensor isometric and isokinetic strength will be assessed by dynamometry.

Full Information

First Posted
February 7, 2017
Last Updated
October 31, 2022
Sponsor
University of Vermont
search

1. Study Identification

Unique Protocol Identification Number
NCT03051984
Brief Title
Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Official Title
Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2017 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
June 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Vermont

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Total knee replacement, or arthroplasty, is the final clinical intervention available to relieve pain and functional limitations related to advanced stage knee osteoarthritis. Despite its beneficial effects, the early post-surgical period is characterized by the erosion of lower extremity muscle size and strength that cause further disability and slow functional recovery. While the detrimental effects of this period on muscle are widely recognized, the mechanisms underlying these adaptations are poorly understood and there are currently no widely-accepted clinical interventions to counter them
Detailed Description
Total knee arthroplasty (TKA) is currently the most common elective surgery in the US and will increase in frequency nearly five-fold by 2030 to 3.5 million surgeries annually. This surgery is most prevalent among older adults with advanced knee osteoarthritis (OA) and its increase is explained primarily by growth in this population. Although TKA reliably reduces joint pain, it fails to correct objectively-measured functional disability due, in part, to dramatic declines in lower-extremity neuromuscular function during the early, postsurgical period. These deficits are never fully remediated, remaining for years after surgery and contributing to persistent disability. Despite these detrimental effects of TKA, the fundamental skeletal muscle adaptations that occur in the early, post-surgical period are poorly defined and understudied and there is currently no widely-accepted, evidence-based intervention to counter these changes. To address this clinical problem, the investigators goals in this application are to define the skeletal muscle structural and functional adaptations following TKA at the whole body, tissue, cellular, organellar and molecular levels in humans in an effort to identify factors contributing to functional disability and to assess the utility of neuromuscular electrical stimulation (NMES) to counter post-surgical muscle adaptations at these same anatomic levels. We hypothesize that TKA fails to remediate physical disability in patients, in part, because of the profound skeletal muscle myofilament and mitochondrial loss and dysfunction that develops during the early, post-surgical period. Moreover, the investigators posit that NMES will improve functional recovery following TKA by countering these early skeletal muscle adaptations. To test this model, the investigators will evaluate participants with knee OA prior to and following TKA for skeletal muscle structure and function at multiple anatomic levels, with patients randomized to receive NMES or sham control intervention during the first 5 weeks post-surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Osteoarthritis

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
48 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NMES
Arm Type
Experimental
Arm Description
Neuromuscular electrical stimulation (NMES) will be administered for 5 weeks post-TKA in the quadriceps of the surgical leg. Treatment will occur 5 days per week, twice daily for 45 minutes on each occasion.
Arm Title
Control
Arm Type
No Intervention
Arm Description
No intervention will be administered during the 5 weeks post-TKA in the surgical leg.
Intervention Type
Device
Intervention Name(s)
Neuromuscular electrical stimulation
Other Intervention Name(s)
NMES
Intervention Description
NMES will be conducted on the quadriceps of the operative leg using a portable stimulation device, starting within 48-72 hrs of surgery. The operative leg will be immobilized at a neutral angle (~30º), with electrodes affixed to the anterior surface of the thigh. Symmetrical, biphasic pulses (400 µs duration at 50 Hz) will be used, with a duty cycle of 25% (10 s on, 30 s off), with patient-selected stimulation intensity to cause visible contractions below pain threshold. NMES sessions will occur 5 d/week, twice daily for 45 min (5 min warm-up) for 5 wks.
Primary Outcome Measure Information:
Title
Cross-sectional area of muscle fibers
Description
Cross-sectional area of skeletal muscle fibers will be evaluated using immunohistochemistry, with specification of all relevant muscle fiber types
Time Frame
Change from baseline cross-sectional area at 5 weeks
Title
Intermyofibrillar mitochondrial content
Description
Area fraction of intermyofibrillar mitochondria will be assessed by electron microscopy
Time Frame
Change from baseline cross-sectional area at 5 weeks
Title
Maximal calcium-activated tension single muscle fiber tension and shortening velocity
Description
Tension (force per unit muscle fiber cross-sectional area) from segments of chemically-skinned single human muscle fibers will be assessed under maximal calcium-activated condition and shortening velocity will be evaluated from isotonic load clamps, with muscle fiber type determined post-measurement by gel electrophoresis
Time Frame
Change from baseline cross-sectional area at 5 weeks
Title
Mitochondrial function
Description
Oxygen consumption rate of isolated muscle mitochondria under adenosine diphosphate stimulation and hydrogen peroxide production
Time Frame
Change from baseline cross-sectional area at 5 weeks
Secondary Outcome Measure Information:
Title
Physical activity level
Description
Physical activity will be assessed by accelerometry.
Time Frame
Change from baseline cross-sectional area at 5 weeks
Title
Quadriceps muscle cross-sectional area
Description
Quadriceps muscle cross-sectional area will be assessed by computed tomography at the mid-thigh.
Time Frame
Change from baseline cross-sectional area at 5 weeks
Title
Physical functional measures
Description
Whole body physical function will be assessed.
Time Frame
Change from baseline cross-sectional area at 5 weeks
Title
Whole muscle strength
Description
Knee extensor isometric and isokinetic strength will be assessed by dynamometry.
Time Frame
Change from baseline cross-sectional area at 5 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: symptomatic, primary knee osteoarthritis (OA) being considered for total knee arthroplasty Exclusion Criteria: knee OA secondary to inflammatory/autoimmune disease untreated/uncontrolled hypertension, diabetes or thyroid disease chronic heart failure, actively-treated malignancy, exercise-limiting peripheral vascular disease, stroke or neuromuscular disease body mass index >38 kg/m2 lower extremity blood clot or known coagulopathies implanted pacemaker/ICD
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael J Toth, PhD
Phone
802-656-7989
Email
michael.toth@uvm.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Patrick Savage
Phone
802-847-4545
Email
patrick.savage@uvmhealth.org
Facility Information:
Facility Name
University of Vermont College of Medicine
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05405
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patrick Savage
Phone
802-847-4545
Email
patrick.savage@uvmhealth.org

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty

We'll reach out to this number within 24 hrs